Anti-diabetic drugs could lower risk of primary and secondary brain cancer
Diabetic patients who take anti-diabetic drugs - known as glitazones – long term had a lower risk of primary and secondary brain cancer compared with diabetic patients on other medications, new research led by the University of Bristol has found.
Source: University of Bristol news - Category: Universities & Medical Training Tags: Health, Research; Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School; Press Release Source Type: news
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Diabetes | Endocrinology | Neurology | Universities & Medical Training